Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CRLBF OTCMKTS:CWBHF NASDAQ:JAZZ NYSEARCA:MJ NYSEARCA:MJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLBFCresco Labs$0.86-5.3%$0.97$0.43▼$2.30$432.37M1.59910,865 shs313,440 shsCWBHFCharlotte's Web$0.43-0.2%$0.61$0.08▼$0.97N/AN/A720,374 shs145,877 shsJAZZJazz Pharmaceuticals$239.66+0.1%$201.35$105.00▼$243.32$15.04B0.27996,474 shs369,056 shsMJAmplify Alternative Harvest ETF$25.16-2.1%$25.27$16.50▼$46.75$125.05M1.1445,077 shs124,169 shsMJAmplify Alternative Harvest ETF$25.16-2.1%$25.27$16.50▼$46.75$125.05M1.1445,077 shs124,169 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLBFCresco Labs+3.18%-3.29%-4.40%-5.40%+32.03%CWBHFCharlotte's Web-3.20%-5.81%-29.12%-43.16%+363.55%JAZZJazz Pharmaceuticals+0.16%+3.61%+20.28%+39.03%+121.11%MJAmplify Alternative Harvest ETF+1.26%-1.83%-0.96%-0.50%+29.73%MJAmplify Alternative Harvest ETF+1.26%-1.83%-0.96%-0.50%+29.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLBFCresco Labs$0.86-5.3%$0.97$0.43▼$2.30$432.37M1.59910,865 shs313,440 shsCWBHFCharlotte's Web$0.43-0.2%$0.61$0.08▼$0.97N/AN/A720,374 shs145,877 shsJAZZJazz Pharmaceuticals$239.66+0.1%$201.35$105.00▼$243.32$15.04B0.27996,474 shs369,056 shsMJAmplify Alternative Harvest ETF$25.16-2.1%$25.27$16.50▼$46.75$125.05M1.1445,077 shs124,169 shsMJAmplify Alternative Harvest ETF$25.16-2.1%$25.27$16.50▼$46.75$125.05M1.1445,077 shs124,169 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLBFCresco Labs+3.18%-3.29%-4.40%-5.40%+32.03%CWBHFCharlotte's Web-3.20%-5.81%-29.12%-43.16%+363.55%JAZZJazz Pharmaceuticals+0.16%+3.61%+20.28%+39.03%+121.11%MJAmplify Alternative Harvest ETF+1.26%-1.83%-0.96%-0.50%+29.73%MJAmplify Alternative Harvest ETF+1.26%-1.83%-0.96%-0.50%+29.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRLBFCresco Labs 3.00BuyN/AN/ACWBHFCharlotte's Web 0.00N/AN/AN/AJAZZJazz Pharmaceuticals 2.84Moderate Buy$241.530.78% UpsideMJAmplify Alternative Harvest ETF 2.04Hold$24.91-0.99% DownsideMJAmplify Alternative Harvest ETF 2.04Hold$24.91-0.99% DownsideCurrent Analyst Ratings BreakdownLatest JAZZ, CWBHF, CRLBF, MJ, and MJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026JAZZJazz Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$232.00 ➝ $301.005/21/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$229.005/19/2026JAZZJazz Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $307.005/7/2026JAZZJazz Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$245.005/6/2026JAZZJazz Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$239.005/6/2026JAZZJazz Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$220.00 ➝ $275.005/6/2026JAZZJazz Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$252.005/6/2026JAZZJazz Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $234.005/6/2026JAZZJazz Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$195.00 ➝ $258.005/6/2026JAZZJazz Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$250.00 ➝ $265.003/31/2026CRLBFCresco Labs Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRLBFCresco Labs$655.85M0.66$0.04 per share22.85$0.49 per share1.76CWBHFCharlotte's WebN/AN/AN/AN/AN/AN/AJAZZJazz Pharmaceuticals$4.44B3.39$16.30 per share14.70$72.24 per share3.32MJAmplify Alternative Harvest ETFN/AN/AN/AN/AN/AN/AMJAmplify Alternative Harvest ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRLBFCresco Labs-$135.41M-$0.39N/AN/AN/A-20.90%-17.98%-4.29%8/6/2026 (Estimated)CWBHFCharlotte's WebN/AN/AN/AN/AN/AN/AN/AN/AN/AJAZZJazz Pharmaceuticals-$356.15M-$0.02N/A10.800.430.66%14.56%5.25%8/4/2026 (Estimated)MJAmplify Alternative Harvest ETFN/AN/A16.86N/AN/AN/AN/AN/AN/AMJAmplify Alternative Harvest ETFN/AN/A16.86N/AN/AN/AN/AN/AN/ALatest JAZZ, CWBHF, CRLBF, MJ, and MJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026CRLBFCresco Labs-$0.03-$0.04-$0.01-$0.04$148.58 million$151.33 million5/5/2026Q1 2026JAZZJazz Pharmaceuticals$4.67$6.34+$1.67$4.43$978.66 million$974.98 million3/31/2026Q1 2026JAZZJazz PharmaceuticalsN/A$6.34N/A$4.43N/A$1.07 billion3/5/2026Q4 2025CRLBFCresco Labs-$0.02-$0.02N/A$0.21$160.87 million$164.04 million2/25/2026Q4 2025JAZZJazz Pharmaceuticals$6.49$6.64+$0.15$3.21$1.17 billion$1.20 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRLBFCresco LabsN/AN/AN/AN/AN/ACWBHFCharlotte's WebN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AMJAmplify Alternative Harvest ETF$0.592.34%N/AN/AN/AMJAmplify Alternative Harvest ETF$0.592.34%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRLBFCresco Labs1.782.511.41CWBHFCharlotte's WebN/AN/AN/AJAZZJazz Pharmaceuticals0.952.041.85MJAmplify Alternative Harvest ETFN/AN/AN/AMJAmplify Alternative Harvest ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRLBFCresco Labs0.05%CWBHFCharlotte's WebN/AJAZZJazz Pharmaceuticals89.14%MJAmplify Alternative Harvest ETFN/AMJAmplify Alternative Harvest ETFN/AInsider OwnershipCompanyInsider OwnershipCRLBFCresco LabsN/ACWBHFCharlotte's WebN/AJAZZJazz Pharmaceuticals4.30%MJAmplify Alternative Harvest ETFN/AMJAmplify Alternative Harvest ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRLBFCresco Labs2,900502.76 millionN/ANot OptionableCWBHFCharlotte's Web260N/AN/ANot OptionableJAZZJazz Pharmaceuticals2,89062.74 million60.05 millionOptionableMJAmplify Alternative Harvest ETFN/A4.97 millionN/ANot OptionableMJAmplify Alternative Harvest ETFN/A4.97 millionN/ANot OptionableJAZZ, CWBHF, CRLBF, MJ, and MJ HeadlinesRecent News About These CompaniesMarijuana Stocks to Watch Before the Next Cannabis RallyMay 19 at 10:00 AM | marijuanastocks.comM3 Top Picks For Marijuana Stocks Investors To See Profits In 2026May 11, 2026 | marijuanastocks.comMTrump’s Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs...May 3, 2026 | marketbeat.comCannabis ETFs: Regulatory Momentum Returns FocusApril 30, 2026 | etftrends.comEFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassificationApril 30, 2026 | reuters.comTop U.S. Marijuana Stocks to Watch in April 2026 as the Sector Heats UpApril 28, 2026 | marijuanastocks.comMA Rally That Didn’t Last: Why Marijuana Shares Reversed After Rescheduling NewsApril 24, 2026 | nai500.comNCannabis Stocks Soared—Than Sank. Here's What Investors Need to Know.April 23, 2026 | investopedia.comFrom high to burnout: Check out these cannabis ETFs on 4/20April 20, 2026 | msn.comCannabis ETFs rally on April 20 after Trump signs order to speed up access to psychedelic treatmentsApril 20, 2026 | marketwatch.comAmplify ETFs Offer Unique Angles on Income, ThematicsApril 17, 2026 | etftrends.comEThe ETFMG Alternative Harvest ETF: Awaiting a Regulatory CatalystMarch 12, 2026 | aktiencheck.deAWhy MJ Is No Longer A SellFebruary 20, 2026 | seekingalpha.comCannabis ETFs Stay High on Drug Rescheduling NewsDecember 17, 2025 | finance.yahoo.com5 ETFs to Watch as Restrictions on Marijuana Set to EaseDecember 12, 2025 | etftrends.comESell The MJ ETFOctober 12, 2025 | seekingalpha.comCannabis Stocks Rally After Trump Highlights CBD Advantages for Older AdultsSeptember 30, 2025 | msn.comDisruptive Theme of the Week: Cannabis Staging a ComebackAugust 19, 2025 | etftrends.comETrump says he's considering reclassifying marijuana as less dangerous drugAugust 11, 2025 | msn.comCannabis stocks, Avantor, Albemarle: Trending TickersAugust 11, 2025 | finance.yahoo.comCannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassificationAugust 11, 2025 | cnbc.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Trump’s Rescheduling of Marijuana Is a Spark for Top Marijuana ETFsBy Jessica Mitacek | May 3, 2026JAZZ, CWBHF, CRLBF, MJ, and MJ Company DescriptionsCresco Labs OTCMKTS:CRLBF$0.86 -0.05 (-5.31%) As of 03:24 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Charlotte's Web OTCMKTS:CWBHF$0.43 0.00 (-0.21%) As of 03:21 PM EasternCharlotte's Web Holdings, Inc. is involved in the farming, manufacture, marketing, and sale of hemp-derived cannabidiol (CBD) wellness products. The company's products categories include hemp extract oil tinctures, such as liquid products; gummies; and capsules, CBD topical creams, and lotions, as well as products for pets under the Charlotte's Web, ReCreate, CBD Medic, CBD Clinic, and Harmony Hemp brands. Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene, cannabigerol, cannabinol, terpenes, flavonoids, and other beneficial hemp compounds. The company distributes its products through retail outlets and health care practitioners, as well as online through its website. It has a collaboration between its CW Labs science division and Colorado State University's College of Agricultural Sciences; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. The company was founded in 2013 and is headquartered in Louisville, Colorado.Jazz Pharmaceuticals NASDAQ:JAZZ$239.66 +0.26 (+0.11%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Amplify Alternative Harvest ETF NYSEARCA:MJ$25.16 -0.54 (-2.10%) As of 03:08 PM EasternThe ETFMG Alternative Harvest ETF (MJ) is an exchange-traded fund that is based on the Prime Alternative Harvest index. The fund tracks an index of global firms engaged in the legal cultivation, production, marketing or distribution of cannabis, cannabinoids or tobacco products. The portfolio is weighted by market cap or equally based on a proprietary system. MJ was launched on Dec 2, 2015 and is managed by ETF Managers Group.Amplify Alternative Harvest ETF NYSEARCA:MJ$25.16 -0.54 (-2.10%) As of 03:08 PM EasternThe ETFMG Alternative Harvest ETF (MJ) is an exchange-traded fund that is based on the Prime Alternative Harvest index. The fund tracks an index of global firms engaged in the legal cultivation, production, marketing or distribution of cannabis, cannabinoids or tobacco products. The portfolio is weighted by market cap or equally based on a proprietary system. MJ was launched on Dec 2, 2015 and is managed by ETF Managers Group. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
